MM&M

Skyrizi claims year-end TV ad crown among Rx, OTC pharma brands

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...
Healio

Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
MM&M

In all-star immuno-matchup, AbbVie’s Skyrizi bests J&J’s Stelara

Funding a head-to-head study against a rival is risky. When that rival’s initials are “J” and “J,” it’s an even riskier bet. However, it’s just the sort of endeavor that appears to have paid off for ...

AbbVie targets $24B in 2025 sales from Skyrizi and Rinvoq, outlines robust mid-single-digit growth

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total ...
PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

AbbVie and Boehringer Ingelheim’s new psoriasis treatment Skyrizi has gained fast-track recommendation from NICE, coming less than three months after its European marketing approval. The positive ...